Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Halperin, Scott A, Ye, Lingyun, MacKinnon-Cameron, Donna, Smith, Bruce, Cahn, Pedro E, Ruiz-Palacios, Guillermo M, Ikram, Aamer, Lanas, Fernando, Lourdes Guerrero, M, Muñoz Navarro, Sergio Raúl, Sued, Omar, Lioznov, Dmitry A, Dzutseva, Vitalina, Parveen, Ghazala, Zhu, Fengcai, Leppan, Laura, Langley, Joanne M, Barreto, Luis, Gou, Jinbo, Zhu, Tao, Mao, Helen, Gagnon, Luc, Tran, Steven-Phay, Khan, Sarwat Tahsin, Becerra Aquino, Amalia Guadalupe, Saldaña Montemayor, Edgar Eduardo, Rivera Martínez, Norma Eréndira, Bohórquez López, Víctor Casildo, Simón Campos, J. Abraham, Pineda Cárdenas, Felipe de Jesús, Chen, Wei, Hou, Lihua, Zhang, Zhe, Corral, Gonzalo, López, Eduardo, Teijeiro, Ricardo, Alzogaray, Maria F., Zaidman, Cesar, Lopardo, Gustavo, Goecke, Bernardo, Feijooó Seoane, Rosa María, Mahmood, Sayed Faisal, Khan, Ejaz Ahmed, Akram, Jayed, Abbas, Salma, Salahuddin, Naseem, Rozhkova, Elena, Zubkova, Tatyana
Published in The Lancet (British edition) (15.01.2022)
Published in The Lancet (British edition) (15.01.2022)
Get full text
Journal Article